Just Say Yes


Image source: smoxx - Shutterstock

What's going on?

Apparently Moderna never listened to Nancy as a kid: the American biotech’s shares got totally high on Wednesday after its encouraging coronavirus vaccine trial results were published late on Tuesday.

What does this mean?

Let’s start with a disclaimer: it’s still early days for Moderna’s potential vaccine. But even so, it’s said to have produced a “robust” immune response in all 45 human patients that took part in its early-stage trial (tweet this). More specifically, the vaccine produced antibodies that could potentially neutralize COVID-19 and give participants at least some protection from the virus. Another disclaimer: there are still several unknowns, including how long that protection might last.

Moderna previously announced plans to enrol 30,000 new participants to take part in late-stage vaccine trials later this month. And now – given the early excitement around its initial trials – investors, governments, and exhausted parents worldwide will be watching the results even more closely.

Why should I care?

For markets: Spoiled for choice.

Moderna’s stock initially rose almost 20% on Wednesday, suggesting investors were hopeful this vaccine will be “the one”. That’s despite all the unknowns of drug development and the stiff competition in the market: hundreds of potential vaccines are in development, after all. News even broke on Wednesday that the University of Oxford’s rival vaccine – set to be produced by AstraZeneca – might be even more effective than Moderna’s. Investors who aren’t brave enough to back a single winner might be inclined to put all the vaccine-developing companies into a single basket and buy that instead.

The bigger picture: A collective sigh of relief.

Even economists’ and companies’ most positive forecasts are heavily caveated with the looming risk of a coronavirus resurgence. But a vaccine could negate that risk and set the global stage for a much-hoped-for – yet increasingly unlikely – V-shaped recovery of both economies and company earnings alike. And that might be why stocks the world over got a nice boost from Moderna’s update.

Originally posted as part of the Finimize daily email.

The top 2 financial news stories in 3 minutes. Join over 800,000 Finimizers

Read next

Chip Chip Chooray

Sign up to Finimize

Get the two most important global financial news stories each day. Sent at midnight UK time.

Get started with one email a day

The top financial news stories in 3 minutes.